Evidence map›Paper›PMID 39501057›Full record

ArticleScientific reports2024

LncRNA DDX11-AS1 promotes breast cancer progression by targeting the miR-30c-5p/MTDH axis.

Yanting Li, Mengsi Zhou, Liu Yang, Shuo Liu, Lixian Yang, Bin Xu, Xiaolong Li, Haijun Zhao, Zhenchuan Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanting LiDepartment of Breast Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang, 050051, China.
Mengsi ZhouDepartment of Breast Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang, 050051, China.
Liu YangDepartment of Breast Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Shuo LiuDepartment of Breast Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Lixian YangDepartment of Breast Surgery, Xingtai People's Hospital, Xingtai, 054001, China.
Bin XuDepartment of Breast Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, 050035, China.
Xiaolong LiDepartment of Breast Surgery, the Fourth Hospital of Shijiazhuang, Shijiazhuang, 050035, China.
Haijun ZhaoDepartment of Breast Surgery, the Fourth Hospital of Shijiazhuang, Shijiazhuang, 050035, China.
Zhenchuan SongBreast Center, Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Shijiazhuang, 050035, China. songzhch@hotmail.com.

Funding

Bethune Cancer Basic Research Program grant no. BCF-NH-ZL-20201119-013Health Commission of Hebei Province grant no. 20230485Natural Science Foundation of Hebei Province grant nos. H2020206365 and H2021206071S&T Program of Hebei grant no. 236Z7719GWu Jieping Medical Foundation grant no. 320.6750.2020/07/17
6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) play a significant role in the occurrence and development of malignant tumours. However, ceRNAs, which are significantly associated with the prognosis of breast cancer (BC), need to be further investigated. Therefore, the current study aimed to investigate the effect of the lncRNA DDX11-AS1 on BC progression. Bioinformatics analysis via a public microarray revealed that DDX11-AS1 was upregulated in BC. The above findings were verified via RT‒qPCR analysis of BC tissues. Additionally, our study revealed that the expression levels of DDX11-AS1 increased with increasing pathological grade and lymph node metastasis. Furthermore, DDX11-AS1 knockdown markedly inhibited the proliferation, migration and invasion abilities of BC cells. Mechanistically, DDX11-AS1 could prevent the degradation of MTDH in BC via competitively binding with miR-30c-5p, which could act as a tumour promoter factor. Additionally, miR-30c-5p was downregulated and MTDH was upregulated in BC cells and tissues. The promoting effect of DDX11-AS1 on BC cells was enhanced by miR-30c-5p silencing and reduced by treatment with MTDH inhibitors. Collectively, the above results suggest that the DDX11-AS1/miR-30c-5p/MTDH axis could be associated with the progression of BC and that DDX11-AS1 could be a potential biomarker and therapeutic target for BC.

Indexed as

Breast NeoplasmsCell MovementCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticMembrane ProteinsMicroRNAsRNA-Binding ProteinsRNA, Long NoncodingCell Line, TumorDEAD-box RNA HelicasesFemaleHumansLymphatic MetastasisMiddle AgedDEAD-box RNA HelicasesMembrane ProteinsMicroRNAsMIRN30a microRNA, humanMTDH protein, humanRNA-Binding ProteinsRNA, Long NoncodingBreast cancerDDX11-AS1MetadherinMiR-30c-5pProgression

Identifiers

PMID39501057
PMCPMC11538490

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.